Getting your player ready...
Cephalon Inc. rejected Valeant Pharmaceuticals International Inc.’s unsolicited $5.7 billion bid, saying the offer is “opportunistic” and undervalues the company’s marketed and experimental medicines.
Denver Post staff and wire reports
